Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?
- PMID: 31088778
- DOI: 10.1016/j.ijrobp.2018.08.025
Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?
Comment on
-
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.J Clin Oncol. 2013 Jan 20;31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub 2012 Oct 15. J Clin Oncol. 2013. PMID: 23071247 Free PMC article. Clinical Trial.
-
Mutational landscape and clonal architecture in grade II and III gliomas.Nat Genet. 2015 May;47(5):458-68. doi: 10.1038/ng.3273. Epub 2015 Apr 13. Nat Genet. 2015. PMID: 25848751
-
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.Neuro Oncol. 2016 Nov;18(11):1529-1537. doi: 10.1093/neuonc/now133. Epub 2016 Jul 1. Neuro Oncol. 2016. PMID: 27370396 Free PMC article. Clinical Trial.
-
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Lancet. 2017. PMID: 28801186 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical